KBC Group
LENZ

KBC Group’s LENZ Therapeutics LENZ Stock Holding History

KBC Group’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$514K Hold
90,425
– – ﹤0.01% 798
2026
Q1 		$827K Buy
+90,425
New +$1.27M ﹤0.01% 738

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

KBC Group's LENZ Position: Q2 2026 in Review

KBC Group held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 90,425 shares worth $514K. The position accounts for ﹤0.01% of the portfolio, ranked #798.

KBC Group first reported a position in LENZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $827K in Q1 2026. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • KBC Group held 90,425 shares of LENZ Therapeutics worth $514K as of Q2 2026.
  • KBC Group left its LENZ Therapeutics share count unchanged in Q2 2026.
  • LENZ Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #798 holding.
  • KBC Group first reported a position in LENZ Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • KBC Group's LENZ Therapeutics position peaked at $827K in Q1 2026.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.